[1] 张之南,沈悌.血液病诊断及疗效标准[M].北京: 科学出版社,2007. [2] MCGOWAN-JORDAN J,SIMONS A,SCHMID M. ISCN2016:an international system for human cytogenetic nomenclature (2016)[M]. Basel:Karger Medical and Scientific Publishers, 2016. [3] DÖHNER H,STILGENBAUER S,BENNER A,et al.Genomic aberrations and survival in chronic lymphocytic leukemia[J].N Engl J Med,2000,343(26): 1910-1916. [4] CHANG C M,WANG S S,DAVE B J,et al.Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study[J].Int J Cancer,2011,129(4):938-947. [5] ZHANG F,YAN L X,LIN S X,et al.Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups[J].Diagn Pathol,2013,8:154. [6] DICKER F,SCHNITTGER S,HAFERLACH T,et al.Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH,IgVH status,and CD38 expression[J].Blood,2006,108(9):3152-3160. [7] LEROUX D,HILLION J,MONTEIL M,et al.T(18;22)(q21;q11) with rearrangement ofBCL2 as a possible secondary change in a lymphocytic lymphoma[J].Genes Chromosom Cancer,1991,3(3):205-209. [8] ADACHI M,TSUJIMOTO Y.Juxtaposition of human bcl-2 and immunoglobulin lambda light chain gene in chronic lymphocytic leukemia is the result of a reciprocal chromosome translocation between chromosome 18 and 22[J].Oncogene,1989,4(9):1073-1075. [9] BRITOS-FRANCO P,RODRÍGUEZ-HERNÁNDEZ I,NAVARRO J T,et al.Translocation (18;22)(q21;q11.2) in B-cell lymphoproliferative disorders: a report of six cases[J].Leuk Lymphoma,2015,56(3): 789-792. [10] BRITOS-FRANCO P,RODRÍGUEZ-HERNÁNDEZ I,NAVARRO J T,et al.Translocation (18;22)(q21;q11.2) in B-cell lymphoproliferative disorders: a report of six cases[J].Leuk Lymphoma,2015,56(3): 789-792. [11] LIN P,JETLY R,LENNON P A,et al.Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature[J].Hum Pathol,2008,39(11):1664-1672. [12] AVILA-CARIÑO J,LEWIN N,TOMITA Y,et al.B-CLL cells with unusual properties[J].Int J Cancer,1997,70(1):1-8. [13] BASEGGIO L,GEAY M O,GAZZO S,et al.In non-follicular lymphoproliferative disorders,IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia[J].Br J Haematol,2012,158(4):489-498. [14] BENTLEY G,PALUTKE M,MOHAMED A N.Variant t(14;18) in malignant lymphoma: a report of seven cases[J].Cancer Genet Cytogenet,2005,157(1):12-17. [15] KOCZKODAJ D,POPEK-MARCINIEC S,ZMORZYSKI S,et al.Examination of clonal evolution in chronic lymphocytic leukemia[J].Med Oncol,2019,36(9): 1-14. [16] PUT N,MEEUS P,CHATELAIN B,et al.Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia[J]. Leukemia,2009,23(6): 17 1201-1204. [17] WONG K F,CHAN J K C.Cytogenetic abnormalities in chronic B-cell lymphoproliferative disorders in Chinese patients[J].Cancer Genet Cytogenet,1999,111(1):55-60. [18] SEITÉ P,LEROUX D,HILLION J,et al.Molecular analysis of a variant 18;22 translocation in a case of lymphocytic lymphoma[J].Genes Chromosom Cancer,1993,6(1):39-44. [19] PÉREZ-CARRETERO C,HERNÁNDEZ-SÁNCHEZ M,GONZÁLEZ T,et al.Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications[J].Int J Cancer,2020,147(10):2780-2792. [20] FANG H,REICHARD K K,RABE K G,et al.IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes[J].Am J Hematol,2019,94(3):338-345. |